Details of the Drug Combination

General Information of Drug Combination (ID: DC1L534)

Drug Combination Name

DFN-15 Terameprocol

Indication

Disease Entry	Status	REF
Adenocarcinoma	Investigative	[1]

Component Drugs

DFN-15 DM3BF9B

Terameprocol DMC3P45

N.A.

Small molecular drug

High-throughput Screening Result

Testing Cell Line: HCC-2998

Zero Interaction Potency (ZIP) Score: 1.36

Bliss Independence Score: 2.88

Loewe Additivity Score: 2.47

LHighest Single Agent (HSA) Score: 1.4

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of DFN-15

Disease Entry	ICD 11	Status	REF
Migraine	8A80	Phase 3	[2]

Indication(s) of Terameprocol

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]

Terameprocol Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Transcription factor Sp1 (SP1)	TTZEP6S	SP1_HUMAN	Modulator	[3]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Astrocytoma	DC17SWV	U251	Investigative	[4]
Clear cell renal cell carcinoma	DCUYSN2	A498	Investigative	[4]
Glioma	DCORIMS	SF-539	Investigative	[4]
Adenocarcinoma	DCU5KYI	NCIH23	Investigative	[1]
Lung adenocarcinoma	DC4NDKD	MDA-MB-231	Investigative	[1]
Pleural epithelioid mesothelioma	DC69APN	NCI-H226	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 DrugCom(s)

References

1	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14.
4	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966